Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance (original) (raw)

Nature volume 390, pages 404–407 (1997)Cite this article

Abstract

Acquired drug resistance is a major problem in the treatment of cancer. Of the more than 500,000 annual deaths from cancer in the United States1, many follow the development of resistance to chemotherapy. The emergence of resistance depends in part on the genetic instability, heterogeneity and high mutational rate of tumour cells2. In contrast, endothelial cells are genetically stable, homogenous and have a low mutational rate. Therefore, antiangiogenic therapy directed against a tumour's endothelial cells should, in principle, induce little or no drug resistance. Endostatin3, a potent angiogenesis inhibitor, was administered to mice bearing Lewis lung carcinoma, T241 fibrosarcoma or B16F10 melanoma. Treatment was stopped when tumours had regressed. Tumours were then allowed to re-grow and endostatin therapy was resumed. After 6, 4 or 2 treatment cycles, respectively, no tumours recurred after discontinuation of therapy. These experiments show that drug resistance does not develop in three tumour types treated with a potent angiogenesis inhibitor. An unexpected finding is that repeated cycles of antiangiogenic therapy are followed by prolonged tumour dormancy without further therapy.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Li, P. L., Schneider, J. A. & Kantor, A. F. in Cancer Medicine 3rd edn Vol. 1(eds Holland, J. F. et al.) 322–339 (Lea & Febiger, Philadelphia, (1993)).
    Google Scholar
  2. Morrow, C. S. & Cowan, K. H. in Cancer Medicine 3rd edn. Vol. 1(eds Holland, J. F. et al.) 618–630 (Lea & Febiger, Philadelphia, (1993)).
    Google Scholar
  3. O'Reilly, M. S. et al . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).
    Article CAS Google Scholar
  4. Brem, H., Goto, F., Budson, A., Saunders, L. & Folkman, J. Minimal drug resistance after prolonged anti-angiogenic therapy with AGM-1470. Surg. Forum XLV, 674–677 (1994).
    Google Scholar
  5. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. BioEssays 13, 31–36 (1991).
    Article CAS Google Scholar
  6. Goldin, A. et al . Current results of the screening program at the division of cancer treatment, National Cancer Institute. Eur. J. Cancer 17, 129–142 (1981).
    Article CAS Google Scholar
  7. Hill, D. L. Review of Cyclophosphamide(Charles C. Thomas, Springfield, Illinois, (1975)).
    Google Scholar
  8. Holmgren, L., O'Reilly, M. S. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149–153 (1995).
    Article CAS Google Scholar
  9. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82, 4–6 (1990).
    Article CAS Google Scholar
  10. O'Reilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689–692 (1996).
    Article CAS Google Scholar
  11. Folkman, J. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757–1763 (1995).
    Article CAS Google Scholar
  12. Folkman, J. Tumor angiogenesis and tissue factor. Nature Med. 2, 167–168 (1996).
    Article CAS Google Scholar
  13. Singh, R. K. et al . Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl Acad. Sci. USA 92, 4562–4566 (1995).
    Article ADS CAS Google Scholar

Download references

Acknowledgements

We thank R. Cotran for analysis of the histological sections, E. Flynn for preparation of the histological sections, K. Keough for help with protein purification, L. DeSantis for photography and S. Moscowitz of Advanced Medical Graphics for help with the figures. This study was supported by a grant to the Children's Hospital from EntreMed (Rockville, Maryland) and by NIH grants. T.B. is a recipient of an Erwin-Schrödinger-Stipendium (Fond zur Förderung der Wissenschaftlichen Forschung, Austria). T. Browder is a recipient of an American Cancer Society Career Development Award.

Author information

Authors and Affiliations

  1. Department of Surgery Department of Pediatric Oncology, Departments of Surgery, Dana Farber Cancer Center, 300 Longwood Avenue, Boston, 02115, Massachusetts, USA
    Thomas Boehm, Judah Folkman, Timothy Browder & Michael S. O'Reilly
  2. Division of Hematology-Oncology Department of Pediatric Oncology, Departments of Surgery, Dana Farber Cancer Center, 300 Longwood Avenue, Boston, 02115, Massachusetts, USA
    Timothy Browder
  3. Department of Pediatric Oncology, Departments of Surgery, Children's Hospital, Dana Farber Cancer Center, 300 Longwood Avenue, Boston, 02115, Massachusetts, USA
    Timothy Browder
  4. Cellular Biology, 300 Longwood Avenue, Boston, 02115, Massachusetts, USA
    Judah Folkman
  5. Pediatrics, 300 Longwood Avenue, Boston, 02115, Massachusetts, USA
    Timothy Browder
  6. Joint Center for Radiation Therapy, Harvard Medical School, 300 Longwood Avenue, Boston, 02115, Massachusetts, USA
    Michael S. O'Reilly

Authors

  1. Thomas Boehm
    You can also search for this author inPubMed Google Scholar
  2. Judah Folkman
    You can also search for this author inPubMed Google Scholar
  3. Timothy Browder
    You can also search for this author inPubMed Google Scholar
  4. Michael S. O'Reilly
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toThomas Boehm.

Rights and permissions

About this article

Cite this article

Boehm, T., Folkman, J., Browder, T. et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.Nature 390, 404–407 (1997). https://doi.org/10.1038/37126

Download citation